DNase I was previously approved by the U.S. Food and Drug Administration to treat mucus buildup in patients with cystic fibrosis.
For the case study, researchers report on a 77-year-old man who had been diagnosed with late-onset Alzheimer’s disease 30 months prior to coming into contact with the researchers. The man was being treated with memantine and had exhibited behavioral disturbances, significant cognitive decline, a decreased ability to engage in activities of daily living and a 20-pound weight loss.
After DNase I was added to the treatment regiment, improvements could be observed just two days later — the patient was able to recognize and remember family members and their names. As treatment continued, the subject became able to dress himself, walk independently, feed himself and use an exercise bike.
“Our results show potential for reversing the effects of a disease that dramatically impacts not only millions of patients around the world, but also their families,” said George Tetz, MD, PhD, scientific officer at HMI. “Our experimental drug has given one patient a new lease on life, and now we are continuing with our tests with the hopes of reversing the devastating effects of Alzheimer’s disease and other incurable diseases like dementia and Parkinson’s.”
More articles on quality:
Joe Biden announces launch of open-access genomic database for cancer research
Children’s hospitals push to improve sleep for patients
Prevention key to reducing racial disparities among stroke victims, study suggests
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
